CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
The Canadian Cancer Trials Group offices at Queen's University remain open however, due to the evolving COVID-19 situation, CCTG staff are now working remotely with a limited support team on-site. The most up-to-date information on the status of the Group is available on this page. If you are a trial patient or family member who has a COVID-19 related question please email us at: info_covid19_public@ctg.queensu.ca
While these times are challenging, we appreciate your patience and input as we all continue to support our centers, hospitals, patients and families.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials.
People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic.
Challenges for patients participating in a trial may arise from; social distancing requirements, cancer centre restrictions, travel limitations, interruptions to the supply of investigational products, or because of the strain on hospital resources. These challenges may lead to difficulties in meeting trial-specified procedures, including following trial-mandated visits or follow-up, and access to laboratory or diagnostic testing.
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
As a faculty that is involved in healthcare, our primary focus in any outbreak is the health and safety of the populations that we serve, and maintaining the working capacity of the healthcare institutions and organizations where we work. Given the rapidly-changing epidemiology of COVID-19, we are using this page to keep Faculty of Health Sciences faculty, staff and students up to date on our protocol.
Keep up to date here.
Queen’s University administrators are actively monitoring reports on the evolving outbreak of coronavirus COVID-19 that can cause acute upper respiratory illness and pneumonia. Protecting the health and safety of our students, staff, and faculty, whether on campus in Kingston, at SmithToronto, the Bader International Study Centre (BISC), or elsewhere in the world, are our primary concerns, and we are continuously assessing what may be required in response to any spread of the virus.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled.
CCTG Network Members,
CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation.
